Ms. Perettie is passionate about improving the care of cancer patients and brings more than two decades of scientific and commercial experience with global biopharmaceutical organizations. Prior to joining Foundation Medicine, Ms. Perettie served as Senior Vice President in global oncology product strategy for Roche’s Oncology unit. Ms. Perettie began her tenure at Genentech as a program team leader for bevacizumab, and she led several successful therapy launches in the U.S. and abroad for Roche and Genentech across the oncology portfolio, including in lung cancer, breast cancer and hematology. In 2012, Ms. Perettie took a hiatus from Genentech to join Sarah Cannon Research Institute as President, Global Development Innovations where she gained invaluable insights into the day-to-day care of people living with cancer. Before joining Genentech, Ms. Perettie lead portfolio management at IVAX Pharmaceuticals and was the director of global program management at Élan Corporation. Her pharmaceutical experience began as a research scientist associate director role at Chiron Corporation.
Cancer genomic profiling can identify germline and medically actionable mutation(s) in cancer predisposition genes. This can present a complex problem for diagnostics labs because of broader implications regarding the patient’s overall health risk, risk of future cancers, and implications for the patient’s family. This panel discussion will focus on how diagnostics labs are addressing this complexity.